Suzhou Vigonvita Biopharmaceutical Co., Ltd. (hereinafter referred to as "Vigonvita") was founded in 2013 and was listed on the Main Board of the Hong Kong Stock Exchange in November 2025 under the stock code 2630.HK.
Vigonvita is an innovation-driven biopharmaceutical company with the mission of improving patients' health and quality of life, dedicated to the development of new drugs in the fields of viral infections, neuropsychiatry, and reproductive health. Vigonvita has built a comprehensive system covering the entire industry chain and full internal control, from innovative drug lead discovery to druggability evaluation, preclinical research, clinical research, manufacturing, and commercialization, rapidly and efficiently translating lead compounds from laboratory research into clinical applications.
Vigonvita has developed a highly competitive and diversified pipeline of innovative drug products, among which two innovative drugs are in the commercialization stage, five drug candidates are in the clinical trial stage, and three candidate compounds are in the preclinical research stage. VV116 is an orally administered nucleoside RNA-dependent RNA polymerase inhibitor with broad-spectrum antiviral potential; its tablet has been approved for marketing in China (trade name: Mindeweiy®) and Uzbekistan (trade name: Mindvy®) for the indication of COVID-19 infection; a Phase II clinical trial of its dry suspension for respiratory syncytial virus (RSV) infection in infants and young children has been completed, with positive clinical trial results, based on which the deutetrabenazine hydrobromide (VV116) dry suspension has been included in the Breakthrough Therapy Designation list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. TPN171 is a highly active and highly selective PDE5 inhibitor with a novel chemical structure; its tablet has been approved for marketing in China (trade name: Angweida®) and Uzbekistan (trade name: Onvita®) for the indication of erectile dysfunction.
Vigonvita will continue to uphold the concept of innovation-driven development, deeply cultivate the fields of viral infections, neuropsychiatry, and reproductive health, help patients relieve pain, and make contributions to society.
What does Suzhou Vigonvita Biopharmaceutical Co., Ltd. require? Who is Suzhou Vigonvita Biopharmaceutical Co., Ltd. hiring? recruitment: Sales占比最多占39.7%,其次是Medical & Health/Beauty & Healthcare占32.8%. What education can get in at ? 本科占比最多占51.7%,其次是大专占36.2%. High education required at ? 硕士占10.3%,博士占1.7%. Work experience required at ? 不限占比最多占62.1%,其次是3-5年占20.7%. Where are the job locations at ? 苏州占比最多占46.6%,其次是上海占12.1%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows